Acura Pharmaceuticals Relies on New AD Pharma Financing

An update from Acura Pharmaceuticals ( (ACUR) ) is now available.

Between December 31, 2025 and January 16, 2026, Acura Pharmaceuticals received three additional $100,000 loans from Abuse Deterrent Pharma (AD Pharma), bringing the principal on its secured promissory note, originally issued on November 10, 2022, to $9,594,279 with about $980,000 of accrued interest at a 5.25% rate as of January 15, 2026, and subject to a higher 7.5% default rate if payments are missed. The short-term funding from AD Pharma, which already controls around 65% of Acura’s common stock (excluding a warrant for 10 million more shares) and whose controller, Mr. Schutte, personally holds roughly 13%, is being used to cover day-to-day operations, but the company warns that without additional financing by the end of January 2026 it may have to sharply scale back or terminate operations, furlough or lay off employees, or seek bankruptcy protection, putting shareholder value at risk and underscoring Acura’s heavy dependence on a single major lender-shareholder for its ongoing viability.

More about Acura Pharmaceuticals

Acura Pharmaceuticals is a specialty drug developer focused on pain management and abuse-deterrent formulations, including products and candidates utilizing its LIMITx and Impede technologies, with its business model heavily reliant on FDA approvals, licensing partnerships and external financing to advance its pipeline toward commercialization.

Technical Sentiment Signal: Sell

Current Market Cap: $33K

For detailed information about ACUR stock, go to TipRanks’ Stock Analysis page.